Erythromycin inhibits prostaglandin F2alpha-induced contractions of myometrium isolated from non-pregnant rats. 2002

Husnu Celik, and Ahmet Ayar, and Abdulkerim Baltaci, and Niyazi Tug
Department of Obstetrics and Gynaecology, Faculty of Medicine, Firat University, Elazig, Turkey.

OBJECTIVE The aim of this study was to investigate the effects of erythromycin on prostaglandin F2alpha (PGF2alpha)-induced contractions of isolated myometrial strips from non-pregnant rats. METHODS In vitro pharmacological study. METHODS Firat University Faculty of Medicine. METHODS Myometrium samples were taken from 55 adult Wistar rats. METHODS Myometrial strips were isolated from mature, non-pregnant Wistar rats. Isometric contractions of these strips were induced with 1 microM PGF2alpha. Effects of 0.01, 0.1, 0.2, 0.5 and 1 mM erythromycin on the frequency and amplitude of these PGF2alpha-induced contractions were recorded. METHODS The inhibition of prostaglandin F2alpha-induced contractions in vitro. RESULTS Application of 0.01 mM erythromycin had no effect on either amplitude or frequency of contractions. However, 0.1, 0.2, 0.5 and 1 mM erythromycin decreased the frequency and amplitude of PGF2alpha-induced contractions. The inhibitory effect of erythromycin on amplitude was 27%, 38%, 54% and 83% (P < 0.05), and that on frequency was 10%, 16%, 32% and 61% (P < 0.05) at 0.1, 0.2, 0.5 and 1 mM concentrations, respectively. CONCLUSIONS The results of this study demonstrate that erythromycin inhibits PGF2alpha-induced contractions in rat myometrium. Because PGF2alpha-induced contractions have been suggested to be involved in the pathogenesis of primary dysmenorrhoea, effects of erythromycin in this clinical entity may present a new approach for the treatment.

UI MeSH Term Description Entries
D010120 Oxytocics Drugs that stimulate contraction of the myometrium. They are used to induce LABOR, OBSTETRIC at term, to prevent or control postpartum or postabortion hemorrhage, and to assess fetal status in high risk pregnancies. They may also be used alone or with other drugs to induce abortions (ABORTIFACIENTS). Oxytocics used clinically include the neurohypophyseal hormone OXYTOCIN and certain prostaglandins and ergot alkaloids. (From AMA Drug Evaluations, 1994, p1157) Oxytocic,Oxytocic Agent,Oxytocic Drug,Uterine Stimulant,Uterine Stimulants,Oxytocic Agents,Oxytocic Drugs,Oxytocic Effect,Oxytocic Effects,Agent, Oxytocic,Agents, Oxytocic,Drug, Oxytocic,Drugs, Oxytocic,Effect, Oxytocic,Effects, Oxytocic,Stimulant, Uterine,Stimulants, Uterine
D011500 Protein Synthesis Inhibitors Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. Protein Synthesis Antagonist,Protein Synthesis Antagonists,Protein Synthesis Inhibitor,Antagonist, Protein Synthesis,Antagonists, Protein Synthesis,Inhibitor, Protein Synthesis,Inhibitors, Protein Synthesis,Synthesis Antagonist, Protein,Synthesis Inhibitor, Protein
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004917 Erythromycin A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins. Erycette,Erymax,Erythromycin A,Erythromycin C,Erythromycin Lactate,Erythromycin Phosphate,Ilotycin,T-Stat,Lactate, Erythromycin,Phosphate, Erythromycin,T Stat,TStat
D005260 Female Females
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D014590 Uterine Contraction Contraction of the UTERINE MUSCLE. Myometrial Contraction,Contraction, Myometrial,Contraction, Uterine,Contractions, Myometrial,Contractions, Uterine,Myometrial Contractions,Uterine Contractions
D015237 Dinoprost A naturally occurring prostaglandin that has oxytocic, luteolytic, and abortifacient activities. Due to its vasocontractile properties, the compound has a variety of other biological actions. PGF2,PGF2alpha,Prostaglandin F2,Prostaglandin F2alpha,9alpha,11beta-PGF2,Enzaprost F,Estrofan,PGF2 alpha,Prostaglandin F2 alpha,9alpha,11beta PGF2,F2 alpha, Prostaglandin,F2alpha, Prostaglandin,alpha, PGF2
D017208 Rats, Wistar A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain. Wistar Rat,Rat, Wistar,Wistar Rats

Related Publications

Husnu Celik, and Ahmet Ayar, and Abdulkerim Baltaci, and Niyazi Tug
January 1998, American journal of obstetrics and gynecology,
Husnu Celik, and Ahmet Ayar, and Abdulkerim Baltaci, and Niyazi Tug
January 1978, Experimentelle Pathologie,
Husnu Celik, and Ahmet Ayar, and Abdulkerim Baltaci, and Niyazi Tug
April 1975, Anesthesiology,
Husnu Celik, and Ahmet Ayar, and Abdulkerim Baltaci, and Niyazi Tug
January 1989, Biochemical and biophysical research communications,
Husnu Celik, and Ahmet Ayar, and Abdulkerim Baltaci, and Niyazi Tug
April 2008, The Journal of endocrinology,
Husnu Celik, and Ahmet Ayar, and Abdulkerim Baltaci, and Niyazi Tug
August 2018, Cellular and molecular biology (Noisy-le-Grand, France),
Husnu Celik, and Ahmet Ayar, and Abdulkerim Baltaci, and Niyazi Tug
October 2020, Anesthesia and pain medicine,
Husnu Celik, and Ahmet Ayar, and Abdulkerim Baltaci, and Niyazi Tug
October 2005, Acta anaesthesiologica Scandinavica,
Husnu Celik, and Ahmet Ayar, and Abdulkerim Baltaci, and Niyazi Tug
September 2011, Acta physiologica Hungarica,
Copied contents to your clipboard!